Comorbidities and lifestyle changes as predictors of the multiple sclerosis prodrome: A prospective cohort study [0.03%]
共病和生活方式变化作为多发性硬化症前驱期预测因素的前瞻性队列研究
Hui Chen,Marianna Cortese,Mario H Flores-Torres et al.
Hui Chen et al.
Background: Multiple sclerosis (MS) is increasingly recognized as having a prodromal phase, characterized by non-specific symptoms preceding demyelinating events, yet prospective, longitudinal assessments of relevant sign...
Silvia Messina,Sithara Ramdas
Silvia Messina
Task-oriented virtual reality and brain functional plasticity in progressive multiple sclerosis: A randomized controlled trial on upper limb rehabilitation [0.03%]
任务导向型虚拟现实和进行性多发性硬化症的大脑功能可塑性：上肢康复的随机对照试验
Mehrnaz Hamedani,Giada Lombardi,Giacomo Boffa et al.
Mehrnaz Hamedani et al.
Background: Motor rehabilitation effectiveness in progressive multiple sclerosis (PMS) remains uncertain. We assessed whether task-oriented (TO) rehabilitation, with or without non-immersive virtual reality, improves uppe...
Reversible area postrema syndrome in a patient with GJB1 mutation mimicking neuromyelitis optica spectrum disorder [0.03%]
叶周蛋白GJB1基因突变的可逆性背侧呼吸中枢综合征1例及其与视神经脊髓炎谱系病鉴别要点分析
Po-Chia Cheng,Yuan-Ting Sun
Po-Chia Cheng
Background: Area postrema syndrome (APS) is a core feature of neuromyelitis optica spectrum disorder (NMOSD). Charcot-Marie-Tooth disease type 1X (CMT1X), caused by gap junction protein beta-1 (GJB1) mutations, can rarely...
A predictive tool for early treatment escalation after initiation of moderate-efficacy therapy in pediatric-onset multiple sclerosis [0.03%]
一种预测工具，用于在儿童期发病的多发性硬化症中，在中效治疗开始后早期进行治疗升级
Nail Benallegue,Fabien Rollot,Pietro Iaffaldano et al.
Nail Benallegue et al.
Background: Early initiation of high-efficacy therapies (HETs) has been associated with improved disease control in pediatric-onset multiple sclerosis (POMS). However, some children remain clinically stable on low-/modera...
Microbiome-derived metabolites from vitamin B2 and B9 pathways modulate MAIT cells from multiple sclerosis patients [0.03%]
维生素B2和B9途径的微生物衍生成分调节多发性硬化患者的MAIT细胞
Jorge Correale,Mariano Marrodan,Maria A Piedrabuena et al.
Jorge Correale et al.
Background: Mucosal-associated invariant T (MAIT) cells recognize microbial vitamin B2 and B9 metabolites via MR1 and have been implicated in multiple sclerosis (MS). How patient-specific gut microbiota shape human MAIT-c...
Spinal cord imaging for multiple sclerosis: Advances, priorities, and opportunities [0.03%]
多发性硬化脊髓影像学：进展、优先项及机遇
Cornelia Laule,Julien Cohen-Adad,Atlee A Witt et al.
Cornelia Laule et al.
The spinal cord plays a central role in the pathophysiology and clinical manifestations of multiple sclerosis (MS), yet remains under-studied compared with the brain. This review summarizes key insights from the 2025 North American Imaging ...
Sex-specific analysis of early disease course and treatment in a German multiple sclerosis cohort [0.03%]
德国多发性硬化队列中早期病程和治疗的性别特异性分析
Philip Lennart Poser,Barbara Gisevius,Marianne Tokic et al.
Philip Lennart Poser et al.
Background: Understanding sex differences in relapsing-remitting multiple sclerosis (RRMS) and initiation of disease-modifying treatments (DMTs) is crucial for tailored approaches. ...
Treatment persistence in paediatric-onset multiple sclerosis: A Swedish nationwide registry study [0.03%]
一项瑞典全国登记处研究：儿童期发病的多发性硬化症患者的治疗持续时间
Fredrik Sandesjö,Kyla A McKay,Katharina Fink et al.
Fredrik Sandesjö et al.
Background: Comparative studies in paediatric-onset multiple sclerosis (PoMS) that also include highly effective monoclonal antibody therapies are rare. O...
Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS) [0.03%]
口服疾病修正治疗的偏好及决策在多发性硬化的随机对照和观察性临床研究（DELIVER-MS）中刍议
Emma C Tallantyre,Sarah M Planchon,Harriet Howard et al.
Emma C Tallantyre et al.
Background: There is growing support for high-efficacy disease-modifying therapy (DMT) in multiple sclerosis (MS), but escalation (ESC) approaches remain common. ...